Kura Oncology (KURA) Research & Development (2014 - 2026)

Kura Oncology (KURA) has 11 years of Research & Development data on file, last reported at $65.3 million in Q1 2026.

• Research & Development for Q1 2026 came in at $65.3 million, up 16.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $215.2 million (up 13.46% YoY), and the FY2025 annual result was $251.1 million, up 47.72% from the prior year.
• Research & Development grew to $65.3 million in Q1 2026 per KURA's latest filing, from $56.0 million in the prior quarter.
• Over five years, Research & Development peaked at $65.3 million in Q1 2026 and troughed at $20.9 million in Q1 2022.
• A 5-year average of $35.7 million and a median of $30.9 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development climbed 2.9% in 2022, then jumped 60.66% in 2024.
• A 5-year view of Research & Development shows it stood at $22.7 million in 2022, then jumped by 43.52% to $32.5 million in 2023, then jumped by 60.66% to $52.3 million in 2024, then advanced by 7.09% to $56.0 million in 2025, then gained by 16.6% to $65.3 million in 2026.
• Business Quant data shows KURA's Research & Development at $65.3 million in Q1 2026, $56.0 million in Q1 2025, and $52.3 million in Q4 2024.